Drug patents …
… from Kazakhstan to Kalamazoo
Manage your formulary budget
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Anticipate generic drug launch
Proactively manage your pharmacy inventory
Find generic entry opportunities
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Novel 2.beta.-morpholino-androstane derivatives|
|Abstract:||Compounds having the formula: ##STR1## wherein R.sub.1 is H or an optionally substituted acyl group having 1-12 carbon atoms, R.sub.2 is H or an acyl group having 1-12 carbon atoms and R.sub.3 is C, N--CH.sub.3 or a direct bond; and mono- or bisquaternary ammonium compounds thereof and acid addition salts of the non- or mono-quaternary ammonium compounds. Process for the preparation of these compounds. Compositions comprising at least one of the above compounds as the active ingredient. The compounds are favorable neuromuscular blocking agents.|
|Inventor(s):||Sleigh; Thomas (Wishaw, GB6), Savage; David S. (New Mearns, GB6), Carlyle; Ian C. (Hamilton, GB6)|
|Assignee:||Akzo N.V. (Arnhem, NL)|
Patent Claim Types:|
see list of patent claims
|Compound; Composition; Formulation;|
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|United Kingdom||8708886||Apr 14, 1987|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Denmark||202888||<disabled in preview>|
|Germany||19575040||<disabled in preview>|
|Germany||3873803||<disabled in preview>|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.